Product Images Tamsulosin Hydrochloride

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 7 images provide visual information about the product associated with Tamsulosin Hydrochloride NDC 63629-8135 by Bryant Ranch Prepack, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Label Image - lbl636298135

Label Image - lbl636298135

This text appears to be a medication label for Tamsulosin capsules. The capsules are olive green and opaque/orange and come in a container of 30 capsules with a recommended dose of 0.4mg. The capsules should be stored at room temperature and kept out of reach of children. The label is from Aurobindo Pharma USA, Inc. and has an NDC code of 6362981351.*

Figure 1 Mean Plasma Tamsulosin Hydrochloride Concentrations Following Single-Dose Administration of Tamsulosin Hydrochloride Capsules 0.4 mg Under Fasted and Fed Conditions (n=8) - tamsulosin fig1

Figure 1 Mean Plasma Tamsulosin Hydrochloride Concentrations Following Single-Dose Administration of Tamsulosin Hydrochloride Capsules 0.4 mg Under Fasted and Fed Conditions (n=8) - tamsulosin fig1

This appears to be a figure (Figure 1) showing mean plasma concentrations of Tamsulosin Hydrochloride capsules of 0.4mg under fed and fasted conditions over time. There are no specific values or measurements provided.*

Figure 2A Mean Change from Baseline in Total AUA Symptom Score (0 to 35) Study 1 - tamsulosin fig2

Figure 2A Mean Change from Baseline in Total AUA Symptom Score (0 to 35) Study 1 - tamsulosin fig2

Figure 2B Mean Change from Baseline in Total AUA Symptom Score (0 to 35) Study 2 - tamsulosin fig3

Figure 2B Mean Change from Baseline in Total AUA Symptom Score (0 to 35) Study 2 - tamsulosin fig3

The figure displays the mean change in total AUA symptom score from the baseline. The study was conducted on different treatments including O=0O—0-08mg, LNt 0.4mg, 3 Placebo. The duration of the study was up to 13 weeks.*

Figure 3A Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 1 - tamsulosin fig4

Figure 3A Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 1 - tamsulosin fig4

The image shows a figure labeled "Figure 3A" that displays the mean increase in peak urine flow rate (in L/sec) of a study, with different treatments including 0.08mg, 0.4mg, and placebo. The figure also shows the mean change (in mL/sec) with respect to the duration of treatment (in weeks).*

Figure 3B Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 2 - tamsulosin fig5

Figure 3B Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 2 - tamsulosin fig5

Chemical Structure - tamsulosin str

Chemical Structure - tamsulosin str

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.